Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05097131 · ClinicalTrials.gov registry record
An Observational Study of Aducanumab-avwa in Participants With Alzheimer's Disease in the US
A clinical trial, sponsored by Biogen.
- Terminated
- Registry status
- 29
- Enrollment target
NCT05097131 is a clinical trial that was terminated before completion, run by Biogen. The registered enrollment target is 29 participants.
The verdict
NCT05097131 was terminated before completion, sponsored by Biogen.
- TERMINATED
- Registry status
- 29 participants
- Enrollment target
Study Summary
This is a prospective, single-arm, multicenter, non-interventional study of aducanumab-avwa as prescribed in the post-marketing setting in the US. Investigators will be prescribing aducanumab-avwa and participants will be treated according to the standard of care (SoC). Participants will be followed up to 5 years after enrollment and data will be collected at routine visits every 6 to 12 months.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2021-11-18 |
| Est. Completion | 2022-05-20 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05097131
The ClinicalTrials.gov registry entry for NCT05097131 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT05097131 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05097131 about?
NCT05097131 is a clinical study titled "An Observational Study of Aducanumab-avwa in Participants With Alzheimer's Disease in the US". This is a prospective, single-arm, multicenter, non-interventional study of aducanumab-avwa as prescribed in the post-marketing setting in the US. Investigators will be prescribing aducanumab-avwa and participants will be treated according to the standard of care (SoC). Participants will be followed...
What is the current status of trial NCT05097131?
This trial is currently terminated. The enrollment target is 29 participants. The study started on 2021-11-18. Estimated completion is 2022-05-20.
Who is sponsoring clinical trial NCT05097131?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.